Completed PHASE3 INTERVENTIONAL 2-arm NCT01146951

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients

Sponsor: Eisai Limited

Interventions Placebo Rufinamide (E2080)

Updated 6 times since 2017 Last updated: Jan 2, 2018 Started: Jun 30, 2010 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Lennox-Gastaut Syndrome and is currently completed. Eisai Limited leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Limited

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Fukuoka, Japan , Goshi-shi, Japan , Hiroshima, Japan , Iwamuma-shi, Japan , Kobe, Japan , Kodaira-shi, Japan , Kokubunji-shi, Japan , Matsuyama, Japan , Moriya-shi, Japan , Nagoya, Japan and 13 more locations